Alkermes 二季度电话会强调 orexin 管线、LYBALVI 覆盖提升及三季度收入指引

Earnings Call Insights: Alkermes (ALKS) Q2 2026
Management View
- “That transition becomes official next week, making this my final earnings call as CEO.” (Chairman & CEO Richard F. Pops) Pops said Alkermes’ “leadership position in orexin development is now quite clear,” and positioned alixorexton as “the only orexin 2 receptor agonist to have demonstrated efficacy and tolerability across both narcolepsy type 1 and narcolepsy type 2 in large Phase 2 studies,” adding that Phase 3 narcolepsy remains “on track for expected completion next year.”
- “Through new contracting arrangements that we believe will help drive increased uptake of LYBALVI, we expanded access strategically with three of the largest Part D plans where LYBALVI is now on formulary.” (Chairman & CEO Pops) He added, “With this expansion, LYBALVI is now covered for more than 80% of insured lives.”
- “Earlier this month, we announced the termination of our agreement with Amneal for an authorized generic of VIVITROL. So, we can say now conclusively that there will be no AG for VIVITROL in 2027.” (Chairman & CEO Pops)
- “During the second quarter, net sales from our proprietary product portfolio increased 34% year-over-year to $411.7 million.” (Chief Commercial Officer Todd Nichols) Nichols said LUMRYZ delivered “net sales of $96.6 million” and the company “exited the quarter with approximately 3,900 patients on therapy.”
- “During the quarter, we generated total revenues of $496 million.” (Senior VP & CFO Joshua Reed) Reed reported “GAAP net income of $0.5 million,” “Adjusted EBITDA was $139.2 million,” and ended Q2 with “approximately $690 million in cash and total investments.”
Outlook
- “As we move into the third quarter, we expect Q3 total revenues in the range of $450 million to $470 million.” (Senior VP & CFO Reed)
- “Looking ahead to the third quarter, we expect Adjusted EBITDA to be in the range of $80 million to $100 million.” (Senior VP & CFO Reed)
- “We expect gross-to-nets to expand in the second half of the year.” (Chief Commercial Officer Nichols) He added, “for the full year, we now expect GTN adjustments in the high 30s” for LYBALVI.
- Compared with Q1, management reiterated full-year net sales ranges for VIVITROL ($460 million to $480 million), ARISTADA ($365 million to $385 million), LYBALVI ($380 million to $400 million), and LUMRYZ (total $350 million to $370 million; Alkermes-recorded $315 million to $335 million). (Chief Commercial Officer Nichols)
Financial Results
- “As Todd outlined, our portfolio of proprietary products generated net sales of $411.7 million.” (Senior VP & CFO Reed) Reed said “Manufacturing and royalty revenues were $84.3 million,” including “$30.6 million from VUMERITY” and “$27.5 million from the long-acting INVEGA products.”
- “Cost of goods sold in the second quarter were $98.1 million.” (Senior VP & CFO Reed) He attributed the increase to “the purchase price fair value accounting of LUMRYZ inventory.”
- “R&D expenses in the quarter were $112.9 million.” (Senior VP & CFO Reed) He tied higher spend to advancing alixorexton and the broader orexin portfolio, including “the Phase 3 alixorexton Brilliance studies,” “Vibrance-3,” and “the ALKS 7290 Phase 1b study in ADHD.”
- “We now expect GAAP net loss in the range of $95 million to $115 million and positive EBITDA in the range of $75 million to $95 million.” (Senior VP & CFO Reed) Reed said the change was driven by “a change in the fair value of contingent consideration of $26.4 million” related to the Avadel CVR milestone.
Q&A
- Umer Raffat, Evercore ISI: asked about adult-to-pediatric translatability, two-week endpoints, and inclusion of AISRS; Executive VP, Chief Risk Officer & COO Blair Jackson responded, “we’ll do the first part of the program in the adult population,” and “we will include AISRS as part of that.”
- Paul Matteis, Stifel: asked how doses were selected for ALKS 7290 and the MS fatigue regulatory path; Executive VP Jackson said, “we used EEG and target engagement,” and for fatigue, “we’re trying to…align with the FDA on that tool moving forward.”
- Leonid Timashev, RBC: asked about orexin pricing strategy; Executive VP Jackson said, “with Takeda coming into the marketplace first…they’ll be definitely establishing a price corridor for the class.”
- Akash Tewari, Jefferies: asked about VOX/valiloxybate pathway and policy (GLOBE/GUARD); Executive VP Jackson said, “The goal here is to establish a bioequivalence pathway if possible,” while Chairman & CEO Pops said, “for Alkermes, we don’t have foreign reference pricing.”
- David Amsellem, Piper Sandler: asked about additional orexin indications and VIVITROL generic risk; Chairman & CEO Pops said, “we do have a number of other ideas,” and on 2027 planning, “we’re not anticipating a generic.”
- Rudy Li, Wolfe: asked LUMRYZ growth drivers and combo use; Chief Commercial Officer Nichols said “the strongest growth segment right now is new to oxybate,” and Executive VP Jackson said, “it’s on us to start to generate some data” on combination.
Sentiment Analysis
- Analysts’ tone was slightly negative to neutral, with persistent probing on ADHD design, orexin pricing/class dynamics, and generic/scheduling risk; examples included pricing specificity requests and competitive framing such as “annualized list and net pricing” and implications of competitor readouts. (Multiple analysts)
- Management tone was positive in prepared remarks and generally confident in Q&A, emphasizing leadership and execution; examples included “highly translatable,” “we think we’ve got it in a good range,” and “we’re not anticipating a generic.” (Executive VP Jackson; Chairman & CEO Pops)
- Versus Q1, Q2 carried more transition and competitive framing, with management more explicit on commercial/access actions and VIVITROL AG removal; Q1 leaned more on acquisition close and early orexin expansion plans. (Chairman & CEO Pops; Chief Commercial Officer Nichols)
Quarter-over-Quarter Comparison
- Leadership and structure shifted from Q1 to Q2 with Pops stating, “making this my final earnings call as CEO,” and Jackson introduced as “incoming CEO.” (Chairman & CEO Pops; Senior VP of Corporate Affairs & IR Sandra Coombs)
- Commercial narrative moved from partial-quarter LUMRYZ contribution in Q1 to “the first full quarter” in Q2, alongside patient-on-therapy growth to “approximately 3,900.” (Chief Commercial Officer Nichols)
- The company’s VIVITROL posture tightened: Q1 discussed scenarios for potential 2027 entry, while Q2 stated, “there will be no AG for VIVITROL in 2027,” and planning is “not anticipating a generic.” (Chairman & CEO Pops)
- Financial guidance emphasis shifted: Q1 updated purchase accounting and projected GAAP net loss ($70 million to $90 million) and EBITDA (positive $105 million to $135 million), while Q2 revised to GAAP net loss ($95 million to $115 million) and EBITDA (positive $75 million to $95 million) due to CVR fair value changes. (Senior VP & CFO Reed)
Risks and Concerns
- “We expect gross-to-nets to expand in the second half of the year.” (Chief Commercial Officer Nichols) Management framed access expansion as a “strategic investment,” with near-term profitability pressure from higher GTN.
- “We do not expect meaningful revenues from CONSTA for the remainder of the year.” (Senior VP & CFO Reed) Reed said Q2 included “the majority of our expected manufacturing revenues for CONSTA for 2026.”
- “The actual timing of that generic market entry remains uncertain.” (Chairman & CEO Pops) Despite stating no AG and planning assumptions, Pops added, “We don’t have perfect visibility in everything.”
Final Takeaway
Management emphasized a near-term leadership transition to Blair Jackson, accelerating orexin pipeline execution (including Phase 3 alixorexton and near-term ALKS 7290 ADHD data), and commercial actions that expand LYBALVI access beyond 80% of insured lives while accepting higher gross-to-net in the second half. Financially, the company guided Q3 total revenue to $450 million-$470 million, highlighted a full-quarter LUMRYZ contribution, and said VIVITROL will have “no AG…in 2027,” while acknowledging uncertainty on the timing of any generic entry.
Read the full Earnings Call Transcript